Abstract

Many medical conditions, treatments and treatment responses are particular to children or differ from their adult equivalents.1^,2 Also, many potentially useful treatments are unlicensed for children. In general practice, at least 1 in 10 medicines prescribed for children are unlicensed or are used 'off-label'.3 These circumstances make the launch of the BNF for Children (BNFC) in September 2005 an important development. We review this new publication.